Shanghai LongRun Mabwell Bio-pharmaceutical Technology Co., Ltd. will build a monoclonal antibody industrialization center in Jinshan, Shanghai. The total gross floor area of the production base exceeds 100,000 square meters and the total investment exceeds RMB 1,600 million. The center is designed and constructed with reference to EU GMP, FDA cGMP and China GMP standards. After completion, it will reach an annual production capacity of 1,000 kg monoclonal antibodies . The first-stage construction of the center is scheduled to commence in 2018 and will be complete in 2021.